CytomX Therapeutics (CTMX) Gains from Sales and Divestitures (2022 - 2026)

CytomX Therapeutics has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 157.56% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 157.56% YoY), and the FY2025 full-year result was $565125.0, down 22.92% from the prior year.
• Gains from Sales and Divestitures for Q1 2026 stood at $1.3 million, up from $565125.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $1.3 million in Q1 2026, with the low at $105000.0 in Q3 2023.
• Historically, Gains from Sales and Divestitures has averaged $438715.2 across 5 years, with a median of $323204.0 in 2023.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures sank 45.81% — and 2024, when it soared 537.49%.
• CytomX Therapeutics' Gains from Sales and Divestitures stood at $134125.0 in 2022, then soared by 64.03% to $220000.0 in 2023, then jumped by 233.27% to $733201.0 in 2024, then decreased by 22.92% to $565125.0 in 2025, then soared by 137.64% to $1.3 million in 2026.
• The last three Gains from Sales and Divestitures figures came in at $1.3 million (Q1 2026), $565125.0 (Q4 2025), and $275000.0 (Q3 2025), per Business Quant data.